Discovery of a putative blood-based protein signature associated with response to ALK tyrosine kinase inhibition

BACKGROUND: ALK tyrosine kinase inhibition has become a mainstay in the clinical management of ALK fusion positive NSCLC patients. Although ALK mutations can reliably predict the likelihood of response to ALK tyrosine kinase inhibitors (TKIs) such as crizotinib, they cannot reliably predict response...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Proteomics
Autors principals: Couëtoux du Tertre, Mathilde, Marques, Maud, McNamara, Suzan, Gambaro, Karen, Hoffert, Cyrla, Tremblay, Lise, Bouchard, Nicole, Diaconescu, Razvan, Blais, Normand, Couture, Christian, Pelsser, Vincent, Wang, Hangjun, McIntosh, Laura, Hindie, Valérie, Parent, Stephane, Cortes, Laetitia, Breton, Yannick-André, Pottiez, Gwenael, Croteau, Pascal, Higenell, Valerie, Izzi, Luisa, Spatz, Alan, Cohen, Victor, Batist, Gerald, Agulnik, Jason
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7006423/
https://ncbi.nlm.nih.gov/pubmed/32055239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12014-020-9269-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars